Cara Therapeutics (NASDAQ:CARA – Get Rating) released its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.04, MarketWatch Earnings reports. During the same period in the prior year, the company earned ($0.47) earnings per share.
CARA stock opened at $7.45 on Tuesday. The company’s fifty day moving average price is $11.69 and its 200-day moving average price is $12.35. Cara Therapeutics has a one year low of $7.40 and a one year high of $18.93. The company has a market capitalization of $399.25 million, a PE ratio of -4.31 and a beta of 1.22.
In related news, CEO Christopher Posner sold 2,006 shares of the firm’s stock in a transaction on Monday, April 4th. The shares were sold at an average price of $12.67, for a total transaction of $25,416.02. Following the completion of the transaction, the chief executive officer now directly owns 201,031 shares of the company’s stock, valued at $2,547,062.77. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have sold 11,235 shares of company stock valued at $130,108. 6.20% of the stock is owned by company insiders.
A number of equities research analysts have weighed in on CARA shares. StockNews.com assumed coverage on shares of Cara Therapeutics in a research note on Thursday, March 31st. They set a “sell” rating for the company. Zacks Investment Research cut shares of Cara Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 2nd. Canaccord Genuity Group dropped their price target on shares of Cara Therapeutics from $33.00 to $29.00 and set a “buy” rating on the stock in a research note on Monday, March 14th. Canaccord Genuity Group decreased their target price on Cara Therapeutics from $33.00 to $29.00 in a report on Monday, March 14th. Finally, HC Wainwright lowered their target price on Cara Therapeutics from $35.00 to $30.00 and set a “buy” rating on the stock in a research report on Monday, March 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, Cara Therapeutics presently has a consensus rating of “Buy” and an average target price of $24.50.
Cara Therapeutics Company Profile (Get Rating)
Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.
- Get a free copy of the StockNews.com research report on Cara Therapeutics (CARA)
- Shopify (NYSE: SHOP) Approaches Key Support Level
- Follow The Money To Cigna
- The Low In Lordstown Motors May Not Be The Last
- Intuitive Surgical is an Intuitive Buy
- MarketBeat Podcast: Barbell Strategy To Strengthen Your Portfolio
Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.